MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

François‐Xavier Mahon(Institut Bergonié), Junia V. Melo(The University of Adelaide)
Blood
February 27, 2003
10.1182/blood.v101.6.2368
Cited by 538

Related Papers

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
|Blood|2006|604
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
|New England Journal of Medicine|2010|385
Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells
|Oncotarget|2015|21